Related Experiment Video
Updated: Feb 12, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
Targeting DYRK1B suppresses the proliferation and migration of liposarcoma cells
Hua Chen1,2, Jacson Shen2, Edwin Choy2
1Department of Emergency Surgery, ShenZhen People's Hospital, 2nd Clinical Medical College of Jinan University, Shenzhen, Guangdong Province, China, 518020.
Abstract:
Liposarcoma is a common subtype of soft tissue sarcoma and accounts for 20% of all sarcomas. Conventional chemotherapeutic agents have limited efficacy in liposarcoma patients. Expression and activation of serine/threonine-protein kinase dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1B (DYRK1B) is associated with growth and survival of many types of cancer cells. However, the role of DYRK1B in liposarcoma remains unknown. In this study, we investigated the functional and therapeutic relevance of DYRK1B in liposarcoma. Tissue microarray and immunohistochemistry analysis showed that higher expression levels of DYRK1B correlated with a worse prognosis. RNA interference-mediated knockdown of DYRK1B or targeting DYRK1B with the kinase inhibitor AZ191 inhibited liposarcoma cell growth, decreased cell motility, and induced apoptosis. Moreover, combined AZ191 with doxorubicin demonstrated an increased anti-cancer effect on liposarcoma cells. These findings suggest that DYRK1B is critical for the growth of liposarcoma cells. Targeting DYRK1B provides a new rationale for treatment of liposarcoma.
Insights
Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1B (DYRK1B) drives liposarcoma growth. Inhibiting DYRK1B with AZ191 or doxorubicin shows therapeutic potential for this soft tissue sarcoma.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Liposarcoma, a prevalent soft tissue sarcoma, shows limited response to conventional chemotherapy.
- Serine/threonine-protein kinase dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1B (DYRK1B) is implicated in various cancer cell growth and survival.
- The specific role of DYRK1B in liposarcoma pathogenesis and progression is currently undetermined.
Purpose of the Study:
- To investigate the functional significance of DYRK1B in liposarcoma.
- To evaluate the therapeutic potential of targeting DYRK1B in liposarcoma models.
Main Methods:
- Tissue microarray and immunohistochemistry were employed to assess DYRK1B expression levels in liposarcoma tissues.
- RNA interference-mediated knockdown and the DYRK1B kinase inhibitor AZ191 were used to study DYRK1B inhibition.
- Cellular assays evaluated the effects on liposarcoma cell proliferation, motility, and apoptosis; combination therapy with doxorubicin was also assessed.
Main Results:
- Elevated DYRK1B expression levels significantly correlated with poorer prognosis in liposarcoma patients.
- Inhibition of DYRK1B, via RNA interference or AZ191 treatment, markedly suppressed liposarcoma cell proliferation and motility, while inducing apoptosis.
- The combination of AZ191 and doxorubicin exhibited enhanced anti-cancer efficacy against liposarcoma cells compared to monotherapy.
Conclusions:
- DYRK1B plays a critical role in promoting liposarcoma cell growth and survival.
- Targeting DYRK1B represents a promising novel therapeutic strategy for liposarcoma treatment.
- Combined inhibition of DYRK1B and conventional chemotherapy may offer improved clinical outcomes for liposarcoma patients.
More Related Videos
Related Concept Videos
Cell Migration
Cell Migration
Cells Coordinate Growth and Proliferation
Abnormal Proliferation
Cancer Cell Migration through Invadopodia
Chemotaxis and Direction of Cell Migration

